Vaxcyte Inc
PCVX31.750USD
-0.840-2.58%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
4.12BCap. mercado
PérdidaP/E TTM
Más Datos de Vaxcyte Inc Compañía
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Información de la empresa
Símbolo de cotizaciónPCVX
Nombre de la empresaVaxcyte Inc
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMr. Grant E. Pickering
Número de empleados414
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección825 Industrial Road, Ste. 300
CiudadSAN CARLOS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94070
Teléfono16508370111
Sitio Webhttps://vaxcyte.com/
Símbolo de cotizaciónPCVX
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMr. Grant E. Pickering
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.32%
The Vanguard Group, Inc.
9.22%
RA Capital Management, LP
9.22%
Fidelity Management & Research Company LLC
7.74%
BlackRock Institutional Trust Company, N.A.
6.97%
Otro
55.54%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
11.32%
The Vanguard Group, Inc.
9.22%
RA Capital Management, LP
9.22%
Fidelity Management & Research Company LLC
7.74%
BlackRock Institutional Trust Company, N.A.
6.97%
Otro
55.54%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
45.86%
Investment Advisor/Hedge Fund
34.47%
Hedge Fund
17.82%
Venture Capital
10.96%
Research Firm
2.30%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.76%
Individual Investor
0.68%
Pension Fund
0.53%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
2.70M
2.1%
-158.03K
-5.52%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
Paradigm BioCapital Advisors LP
1.70M
1.32%
+273.69K
+19.24%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
iShares Morningstar Small-Cap ETF
0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Dow Jones U.S. ETF
0%
Avantis US Equity ETF
0%
ProShares UltraPro Russell2000
0%
Schwab 1000 Index ETF
0%
Proshares Ultra Russell 2000
0%
iShares Morningstar Small-Cap ETF
Proporción0%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
iShares Dow Jones U.S. ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Schwab 1000 Index ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
